The ALCANZA trial was a Phase 3 investigation examining BV in C-ALCL and MF patients. It aimed to evaluate overall survival, progression free survival with the therapy, as well as quality of life improvements compared to the physician’s choice therapy.

The trial included 128 patients who were randomized to either receive the BV treatment (64 patients) or the physician’s choice treatment (64 patients).